Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young
Executive Summary
Several of this year’s biggest biopharma M&A deals provide significant tax benefits. “The Pink Sheet” brushes up on how multinational companies are managing tax considerations and examines more closely the core taxation issues for the industry.
You may also be interested in...
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Sen. Baucus Still Has Ambitious Agenda: Tax Reform, Deficit Reduction, ACA
Finance Committee chairman decides not to seek re-election in 2014. He has a history of working productively with the drug industry on major legislation such as health reform, the Medicare Modernization Act and PDUFA reauthorizations.
Pharmas Among Biggest Cash Hoarders, Moody’s Finds
A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.